Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

West Melbourne, Australia Clinical Trials

A listing of West Melbourne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (39) clinical trials

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.

Phase

1.71 miles

Learn More »

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

For each potential subject, there is a 28-day screening and eligibility assessment period before enrollment; the first dose of study treatment will be administered on Day 1 of Cycle 1 (C1D1) (Safety population). Subjects will continue to receive their assigned treatment throughout the study until the occurrence of confirmed disease ...

Phase

1.71 miles

Learn More »

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

The primary objectives are to determine the safety and efficacy of oral larotrectinib in pediatric patients with advanced solid or primary central nervous system (CNS) tumors. The secondary objectives comprise e.g. the determination of the pharmacokinetic properties, the maximum tolerated dose/ recommended dose and the tumor-type specific efficacy of larotrectinib. ...

Phase

1.87 miles

Learn More »

A Study to Evaluate the Safety Reactogenicity and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

RSV is considered the most important cause of serious acute respiratory illness in children under 5 years of age. Ad26.RSV.preF (JNJ-64400141) investigational vaccine is a replication-incompetent serotype 26 adenoviral vector (Ad26) containing a deoxyribonucleic acid (DNA) transgene that encodes for the F protein derived from the respiratory syncytial virus (RSV) ...

Phase

1.87 miles

Learn More »

Study of Pharmacokinetics Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

The study is an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages 28 days to <18 years old with either grade II-IV aGvHD or grade II-IV SR-aGvHD. This trial will utilize ...

Phase

1.87 miles

Learn More »

A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks. The study consists of 2 parts. Part 1, the Phase 1b, is an open-label multiple dose escalation study to evaluate the safety and tolerability of KZR-616 in ...

Phase

1.87 miles

Learn More »

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

Phase

1.87 miles

Learn More »

A Study of TAS-120 in Patients With Advanced Solid Tumors

Phase 1 Dose Escalation Phase 1 Dose Escalation has been completed as of Dec 2017 Phase 1 Dose Expansion: (CLOSED) Up to approximately 185 patients will be enrolled among the 8 groups as outlined below: Group 1- CCA (iCCA or eCCA) with FGFR2 gene fusions. Group 2- CCA (iCCA or ...

Phase

2.01 miles

Learn More »

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Several groups have explored the possible synergistic interactions between proteasome and HDAC inhibitors in malignant hematopoietic cells. Bortezomib and HDACIs synergistically induce apoptosis, mitochondrial injury (via BAX), ROS generation and oxidative injury in human leukemia and myeloma cells. In view of this evidence, we are proposing a trial to examine ...

Phase

2.01 miles

Learn More »

Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors

Blocking antibodies targeting PD-1 have achieved remarkable results in the treatment of many types of tumors. However, it is also worth noting that this therapeutic strategy typically achieves a < 30% objective response rate (ORR) as a monotherapy in patients whose tumors exhibit low positive PD-L1 expression and/or are microsatellite ...

Phase

2.01 miles

Learn More »